Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 11, 2021 22:03 ET | Source: NexImmune, Inc.

NexImmune Announces Pricing of Upsized Initial Public Offering

GAITHERSBURG, Md., Feb. 11, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to...
January 19, 2021 08:30 ET | Source: NexImmune, Inc.

NexImmune Appoints Healthcare Innovator Grant Verstandig as New Board Member

Verstandig currently serves as Chief Digital Officer of UnitedHealth Group, where he is responsible for UnitedHealth Group’s digital platform and capabilities Founder of digital consumer healthcare...
January 18, 2021 08:30 ET | Source: NexImmune, Inc.

Immunotherapy Veteran Robert Knight, MD, Joins NexImmune as Chief Medical Officer

With more than 25 years of clinical development leadership experience at companies such as Celgene and Kite Pharmaceuticals, Dr. Knight will now lead the clinical development of NexImmune’s novel...
January 04, 2021 06:00 ET | Source: NexImmune, Inc.

NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor

Zeldis formerly served as Celgene CMO and CEO of Celgene Global HealthWeber is a renowned melanoma specialist and leading immunotherapy translational and clinical scientistBoth will help NexImmune...
December 07, 2020 17:31 ET | Source: NexImmune, Inc.

Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition

GAITHERSBURG, Md., Dec. 07, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to...
November 04, 2020 14:00 ET | Source: NexImmune, Inc.

NexImmune to Highlight Preliminary Results from Phase 1/2 Trial of NEXI-001 via Oral Presentation at 62nd ASH Annual Meeting

GAITHERSBURG, Md., Nov. 04, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunotherapies, announced today that an...
October 27, 2020 08:30 ET | Source: NexImmune, Inc.

NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia

GAITHERSBURG, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunotherapies, announced today that it...
October 06, 2020 08:30 ET | Source: NexImmune, Inc.

First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma

GAITHERSBURG, Md., Oct. 06, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing a portfolio of unique non-genetically-engineered T cell immunotherapies, announced...
September 23, 2020 08:30 ET | Source: NexImmune, Inc.

NexImmune Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of NEXI-001 in Relapsed Acute Myelogenous Leukemia (AML)

Company is using its Artificial Immune Modulation (AIM) nanoparticle technology to develop T cell immunotherapies for patients with relapsed and/or refractory hematologic malignancies GAITHERSBURG,...
June 01, 2020 09:37 ET | Source: NexImmune, Inc.

NexImmune to Present at the Jefferies Virtual Healthcare Conference

GAITHERSBURG, Md., June 01, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharma company advancing a new generation of nanoparticle-based therapies for targeted immune system response,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right